Publications
172
Citations
1,794
Est. group size
—
Recurring co-author estimate
Active years
19
Publishing since 2008
Tim Lautenschlaeger conducts cancer research focused on radiation oncology and the molecular biology of tumors. Their work spans clinical trials in cancers such as muscle-invasive bladder cancer and laboratory studies of the molecular and metabolic mechanisms driving lung cancer and brain tumors (glioblastoma). A recurring theme is identifying molecular markers—like microRNAs and DNA mutations detectable in blood—that predict tumor behavior and patient outcomes.
Publication activity has been variable over the past decade, with peaks in 2018 and 2023 and lower counts in the most recent years, averaging about 8 publications per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial
International Journal of Radiation Oncology*Biology*Physics · 2024
- Stable Isotope-Assisted Untargeted Metabolomics Identifies ALDH1A1-Driven Erythronate Accumulation in Lung Cancer Cells
Biomedicines · 2023
- Supplementary Figures from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
2023
- Supplementary Figure Legends from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
2023
- Supplementary Tables from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
2023
- Supplementary data from <i>TERT</i> Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with <i>IDH</i> Wild-Type Glioblastomas: A Pilot Prospective Study
2023
- Supplementary Table 1 from <i>TERT</i> Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with <i>IDH</i> Wild-Type Glioblastomas: A Pilot Prospective Study
2023
- Supplementary Figures from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
2023
- Supplementary Tables from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
2023
- Supplementary Figure Legends from MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
2023
- Supplemental Information, Supplementary Tables 1-2 from Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation
2023
- Supplemental Figure S1 to S14 Legends from Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation
2023
- Supplementary Figures S1 to S14 from Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation
2023
- Supplementary Table 1 from <i>TERT</i> Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with <i>IDH</i> Wild-Type Glioblastomas: A Pilot Prospective Study
2023
- Supplementary data from <i>TERT</i> Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with <i>IDH</i> Wild-Type Glioblastomas: A Pilot Prospective Study
2023
- International Journal of Radiation Oncology*Biology*Physics×33
- Journal of Clinical Oncology×9
- Clinical Lung Cancer×4
- Author eBooks×4
- Reports of Practical Oncology & Radiotherapy×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile